Frank V Fossella - JoVE Visualize

Showing results (11-20 of 62) with videos related to

Pageof 7

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2005

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancerFrancisco Robert, George Blumenschein, Roy S Herbst, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007

Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapyOzden Altundag, David J Stewart, Frank V Fossella, et al.

Seminars in Oncology|July 15, 2005

Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapyRitsuko Komaki, Joe Y Chang, Xifeng Wu, et al.

Investigational New Drugs|March 11, 2016

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumorsManisha H Shah, Paul Lorigan, Mary E R O'Brien, et al.

Oncology (Williston Park, N.Y.)|July 31, 2003

Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancerFaye M Johnson, Jonathan M Kurie, Beverly O Peeples, et al.

Journal of the National Cancer Institute|June 7, 2007

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysisAndrea Ardizzoni, Luca Boni, Marcello Tiseo, et al.

American Journal of Clinical Oncology|August 19, 2009

Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapyWilliam N William, Fadlo R Khuri, Frank V Fossella, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005

High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapyJoe Y Chang, Ritsuko Komaki, Ryohei Sasaki, et al.

Cancer|March 13, 2010

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinomaWilliam N William, James Uyeki, Faye M Johnson, et al.

International Journal of Radiation Oncology, Biology, Physics|June 17, 2008

Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancerRalph G Zinner, Ritsuko Komaki, James D Cox, et al.

Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:

Pageof 7

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2005

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancerFrancisco Robert, George Blumenschein, Roy S Herbst, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007

Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapyOzden Altundag, David J Stewart, Frank V Fossella, et al.

Seminars in Oncology|July 15, 2005

Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapyRitsuko Komaki, Joe Y Chang, Xifeng Wu, et al.

Investigational New Drugs|March 11, 2016

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumorsManisha H Shah, Paul Lorigan, Mary E R O'Brien, et al.

Oncology (Williston Park, N.Y.)|July 31, 2003

Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancerFaye M Johnson, Jonathan M Kurie, Beverly O Peeples, et al.

Journal of the National Cancer Institute|June 7, 2007

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysisAndrea Ardizzoni, Luca Boni, Marcello Tiseo, et al.

American Journal of Clinical Oncology|August 19, 2009

Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapyWilliam N William, Fadlo R Khuri, Frank V Fossella, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005

High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapyJoe Y Chang, Ritsuko Komaki, Ryohei Sasaki, et al.

Cancer|March 13, 2010

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinomaWilliam N William, James Uyeki, Faye M Johnson, et al.

International Journal of Radiation Oncology, Biology, Physics|June 17, 2008

Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancerRalph G Zinner, Ritsuko Komaki, James D Cox, et al.

Pageof 7